A Phase 1 interventional study of Cilofexor in Primary Sclerosing Cholangitis and Compensated Cirrhosis, sponsored by Gilead Sciences. Terminated at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-27.
Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Cholangitis, Sclerosing with a site in United States — 19 open to participants now, 22 under way, 2 of them phase 3. Cholangitis, Sclerosing · United States.
Among the 75 studies in Cholangitis, Sclerosing with a site in United States, this one is the 44th largest by enrollment of the 57 interventional ones that give a count, is one of 5 that started in 2019, is one of 19 in phase 1, and was the 51st registered.
150 studies on the registry are indexed under Cholangitis, Sclerosing; 40 are open to participants now.
Browse Cholangitis, Sclerosing studies →19 of the 75 studies in Cholangitis, Sclerosing with a site in United States are open now. Recruiting first, the newest first:
Ipsen · Sites in United States, Argentina, Australia and 22 more countries
Ages 18–75
Takeda · Sites in United States
Ages 18–68 · Healthy volunteers
LISCure Biosciences · Sites in United States
Ages 18–75
Mayo Clinic · Sites in United States
Ages 18–75
Elizabeth C. Verna · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 30 Cholangitis, Sclerosing studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 31 · Phase 3 6
First in 1997; this study’s year is marked. 5 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 33 across 95 interventional studies indexed under Cholangitis, Sclerosing.
Median enrollment 27 across the 57 interventional studies, 129 across the 18 observational. Of the 48 that completed or were terminated, 25 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 75 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Gilead Sciences has 7 studies filed under Cholangitis, Sclerosing — fewer than ten, so there is no comparison to draw.
4 of the studies in Cholangitis, Sclerosing with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06197308University of MinnesotaEvaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC | 2027-03-31 |
| NCT05295680Aparna GoelOral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis. | 2027-05 |
| NCT05835505Brigham and Women's HospitalDetoxification of the Liver In PSC (Dolphin) | 2027-05-01 |
| NCT05912387Stanford UniversityStatin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study | 2027-05-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 75 studies in Cholangitis, Sclerosing with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to assess the safety and tolerability of escalating doses of cilofexor (CILO) in participants with primary sclerosing cholangitis (PSC) and compensated cirrhosis.
Key Inclusion Criteria:
Individual has the following laboratory parameters at the Screening visit, as determined by the central laboratory:
Key Exclusion Criteria:
Current or prior history of any of the following
Current moderate to severely active inflammatory bowel disease (IBD) (including ulcerative colitis, Crohn's disease, and indeterminate colitis).
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive escalating doses of cilofexor 30 mg, 60 mg, and 100 mg.
Drug: Cilofexor
Tablets administered orally once daily
Also known as: CILO, GS-9674
Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)
Treatment-emergent adverse events (TEAEs) were either defined any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug or any AEs leading to premature discontinuation of study drug.
Time frame: First dose date up to 12 weeks plus 30 days
Percentage of Participants Who Experienced Treatment Emergent Serious Adverse Events (SAEs)
A treatment emergent SAE was defined as an event that, at any dose, resulted in the following: death ; life-threatening situation; in-patient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; a congenital anomaly/birth defect; a medically important event or reaction: such events may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent one of the other outcomes constituting SAEs.
Time frame: First dose date up to 12 weeks plus 30 days
Percentage of Participants Who Experienced Laboratory Abnormalities
Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug plus 30 days. Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening.
Time frame: First dose date up to 12 weeks plus 30 days
Participants were enrolled at study sites in the United States.
| Milestone | Cilofexor |
|---|---|
| Started | 11 |
| Completed | 10 |
| Not completed | 1 |
| Withdrew: Withdrew consent | 1 |
Treatment-emergent adverse events (TEAEs) were either defined any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug or any AEs leading to premature discontinuation of study drug.
| percentage of participants | Cilofexor |
|---|---|
| Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) | 81.8 |
A treatment emergent SAE was defined as an event that, at any dose, resulted in the following: death ; life-threatening situation; in-patient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; a congenital anomaly/birth defect; a medically important event or reaction: such events may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent one of the other outcomes constituting SAEs.
| percentage of participants | Cilofexor |
|---|---|
| Percentage of Participants Who Experienced Treatment Emergent Serious Adverse Events (SAEs) | 0 |
Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug plus 30 days. Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening.
| percentage of participants | Cilofexor |
|---|---|
| Grade 1 | 54.5 |
| Grade 2 | 36.4 |
| Grade 3 | 9.1 |
| Grade 4 | 0 |
Collected over All-Cause Mortality: Enrollment up to 17 weeks; Adverse Events: First dose date up to 12 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cilofexor | 0/11 (0%) | 0/11 (0%) | 9/11 (81.8%) |
| Event | Cilofexor |
|---|---|
| PruritusSkin and subcutaneous tissue disorders | 8/11 |
| NauseaGastrointestinal disorders | 2/11 |
| FatigueGeneral disorders | 2/11 |
| Upper respiratory tract infectionInfections and infestations | 2/11 |
| HeadacheNervous system disorders | 2/11 |
| VertigoEar and labyrinth disorders | 1/11 |
| ConstipationGastrointestinal disorders | 1/11 |
| Defaecation urgencyGastrointestinal disorders | 1/11 |
| DiarrhoeaGastrointestinal disorders | 1/11 |
| Ill-defined disorderGeneral disorders | 1/11 |
Safety Analysis Set included all participants who took at least 1 dose of study drug.
| Age, Continuous(years) | Cilofexor |
|---|---|
| Mean | 49 ± 14.1 |
| Sex: Female, Male(Participants) | Cilofexor |
|---|---|
| Female | 5 |
| Male | 6 |
| Race/Ethnicity, Customized(Participants) | Cilofexor |
|---|---|
| Race — Black or African American | 1 |
| Race — White | 10 |
| Race/Ethnicity, Customized(Participants) | Cilofexor |
|---|---|
| Ethnicity — Not Hispanic or Latino | 10 |
| Ethnicity — Hispanic or Latino | 1 |
| Region of Enrollment(Participants) | Cilofexor |
|---|---|
| United States | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2019 to primary completion in Sep 2021, 22 months.
Results were first posted in Jul 2023, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cilofexor